Key facts
- This page summarizes Linda Liu's Form 4 filing for NextCure, Inc. (NXTC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2022, 15:22.
Linda Liu - 31 Jan 2022 Form 4 Insider Report for NextCure, Inc. (NXTC)
- Reporting relationship
- SVP, Research
- Issuer ticker
- NXTC
- Reported as of
- 31 Jan 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Steven P. Cobourn, as attorney-in-fact for Linda Liu
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Linda Liu filed Form 4 for NextCure, Inc. (NXTC) on 02 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NXTC
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +65,600
- Change %
- Price
- $0.000000
- Shares after
- 65,600
- Date
- 31 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,600
- Exercise price
- $5.57
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One fourth of the option vests on January 31, 2023. The remainder vests in 36 monthly installments beginning on February 28, 2023.